WebOct 19, 2024 · Darzalex Faspro (daratumumab and hyaluronidase-fihj) is a combination of daratumumab, a CD38-directed cytolytic antibody, and hyaluronidase, an endoglycosidase, indicated for the treatment of multiple myeloma and light chain (AL) amyloidosis. multiple myeloma in combination with bortezomib, melphalan and prednisone (Darzalex Faspro … WebApr 11, 2024 · DARZALEX FASPRO DARZALEX FASPRO is co-formulated with recombinant human hyaluronidase, Halozyme’s (CA, USA) proprietary ENHANZE ® drug-delivery technology. ENHANZE enables the route of administration of some therapeutics to be modified and can facilitate subcutaneous rather than intravenous delivery options.
Coding & Billing Janssen CarePath for Healthcare Professionals
WebMar 14, 2024 · Mild reactions can cause symptoms such as hives, skin rash, or fever. However, in rare cases, Darzalex may cause severe infusion reactions. Symptoms of a more serious reaction include: swelling ... WebApr 3, 2024 · The median time to onset was 3.2 hours (range: 4 minutes to 3.5 days). Of the 140 systemic administration-related reactions that occurred in 77 patients, 121 (86%) occurred on the day of DARZALEX FASPRO ® administration. Delayed systemic administration-related reactions have occurred in 1% of the patients. st paul thorndale tx
DailyMed - DARZALEX FASPRO (daratumumab and …
WebDARZALEX® ®(daratumumab) injection DARZALEX (daratumumab) injection 2 FULL PRESCRIBING INFORMATION 1 INDICATIONS AND USAGE DARZALEX is indicated for the treatment of adult patients with multiple myeloma: • in combination with lenalidomide and dexamethasone in newly diagnosed patients who are ineligible for autologous stem cell … WebDec 23, 2024 · DARZALEX FASPRO is a combination of daratumumab, a CD38-directed cytolytic antibody, and hyaluronidase, an endoglycosidase, indicated for the treatment of … WebNo dose reductions of DARZALEX FASPRO are recommended. Consider withholding DARZALEX FASPRO to allow recovery of blood cell counts in the event of … st paul thorndale